Faculty Interviews from the 29th Annual International Prostate Cancer Update
On The Role of Genotypic and Phenotypic Biomarkers in Prostate Cancer
David M. Albala, MD
Crouse Hospital and Associated Medical Professionals
Syracuse, NY, USA
On the Role of Axumin PET Scans in Patients with Biochemical Recurrent Prostate Cancer
Gerald L. Andriole, Jr., MD
Washington University
St. Louis, MO, USA
On Advanced Radiation Oncology Techniques in Prostate Cancer
Steven E. Finkelstein, MD
Advanced Urology Institute
Panama City, FL, USA
On the Optimal Application of PSA Testing
Richard G. Harris, MD
UroPartners
Chicago, IL, USA
On Risk-Stratifying Men for Prostate Cancer Early in Life
Karim Kader, MD, PhD
UC San Diego Health System
La Jolla, CA, USA
On the Interactions Between the AUA, CPT, and RUC
Ronald P. Kaufman, MD
Albany Medical College
Albany, NY, USA
On a High-Resolution Ultrasound Technology for Detecting Prostate Cancer
Laurence Klotz, MD
University of Toronto
Toronto, ON, Canada
On Abiraterone and Flare
Phillip J. Koo, MD
Banner MD Anderson Cancer Center
Phoenix, AZ, USA
On the Field of Theranositics and Radioligand Therapies
Phillip J. Koo, MD
Banner MD Anderson Cancer Center
Phoenix, AZ, USA
On Second Opinion Diagnosis in Prostate Pathology
Francisco G. La Rosa, MD
University of Colorado, Denver
Aurora, CO, USA
On the Current State of M0 Prostate Cancer
Neal D. Shore, MD
Carolina Urologic Research Center
Myrtle Beach, SC, USA
On the Future of Precision Diagnosis of Prostate Cancer
Faina Shtern, MD
AdMeTech Foundation
Boston, MA, USA
On the Possibility of 3D Mapping Biopsy Replacing MRI
Nelson N. Stone, MD
Mount Sinai School of Medicine
New York, NY, USA